Invest in Vironix Health Inc.

We’ve created software that can potentially save lives through early detection of Heart failure, asthma, COPD, and other acute respiratory illnesses.

The Problem:

Cardiovascular diseases are the leading cause of death globally.

🙍 That’s one death every 56 seconds.

Either you or someone you know has been impacted by heart or lung disease.

People diagnosed with or at risk of Heart Failure, COPD, Asthma, & Acute Respiratory Illness face constant risk of death, hospitalization, massive healthcare expenditures, and persistent anxiety driven by singular health deterioration episodes (exacerbations & infections) that, if detected and managed early, are readily addressed at home with diet, medication, and rest.

The cost of preventable heart and lung disease to employers and health insurance providers is over $400 Billion a year.

🧠 The Solution: VIRONIX AI

VIRONIX makes AI-enabled therapeutic monitoring software that helps people to catch and intervene early on dangerous health deterioration episodes.

Our key differentiation is that we simultaneously:

1) 💖outperform standard-of-care in identifying and triaging heart and lung flare-ups

2) 🧬reduce patient symptom severity, raise medication adherence, and increase quality-of-life

3) 🧑🏻‍⚕generate significant new revenue for caregivers (up to $300 per patient per month) through established health insurance reimbursement codes.

4) 🎲provide AI-personalized and gamified software along with biometric monitoring devices to patients free of charge.

5) 🩺seamlessly integrate into existing physician/patient software/hardware

Consequently, patient safety and health go up, provider revenue goes up, and global mortality/morbidity goes way down.

Our team comprises the top physicians, technologists, healthcare entrepreneurs, and data scientists in the world with past successful exits, large professional networks, resources, and numerous peer-reviewed publications. 

We also have R&D collaborations with Oxford University, Duke University, and Kaiser Permanente to name a few.

To learn more about Vironix AI, watch our documentary with actor Dennis Quaid:

** Note that Vironix's AI products evolve and improve every day. The above figures include peer-reviewed algorithm performance and clinical efficacy data spanning 6 years of our research. Vironix's current AI capabilities incorporate methods from the above studies, but our products implement a broader and more advanced set of prediction models and user workflows.**

Check out our interview with Pulmonologist, Dr. Nicholas Wysham to hear his thoughts on Vironix AI: 

VIRONIX requires no upfront investment from patients or physicians. We don’t get paid until our customers get paid!

We charge approximately $300 per patient per month, paid for by insurers under established CPT codes. 

To date, VIRONIX has:

• a paying beta customer,
• a completed POC with an $8B ARR system integration partner,
• strong clinical efficacy data,
• letters of intent for patient monitoring, SaaS, and employer wellness contract representing a $1.8 billion revenue opportunity.

Vironix represents:

• Strong customer adoption following successful commercial pilots
• Attractive ROI
• Exit potential via M&A/IPO

🥇We are doing it better than anyone else:

How we plan to grow your investment:

We’re raising capital to fund pilot completion, product development, and go-to-market strategy to aggressively bring these invaluable healthcare products to patients, providers, and global institutions.